Transcription of Ophthalmic Preparations
{{id}} {{{paragraph}}}
Example: tourism industry
Ophthalmic Preparations
Vol. 39(5) [Sept. Oct. 2013] (P) \\usp-netapp2\share\SHARE\USPNF\PRINTQ\p ager\xmlIn\ Aug. 28, 2013 11:04:44 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Ophthalmic Preparations Dale S. Aldricha, Cynthia M. Bacha, William Brownb, Wiley Chambersa,c, Jeffrey Fleitmana, Desmond Huntb, Margareth R. C. Marquesb,d, Yana Millee,c, Ashim K. Mitraa, Stacey M. Platzera, Tom Ticea, George W. Tina ABSTRACT General chapter Ophthalmic Ointments 771 is being revised and renamed Ophthalmic Preparations Quality Tests 771and will include descriptions of and quality tests for all dosage forms that can be applied in the eye. A companion chapter, Ophthalmic Preparations Quality Tests 771, will address performance tests such as dissolution and drug release. This Stimuli article presents the rationale for these changes, along with descriptions and characteristics related to novel Ophthalmic dosage forms.
transport molecules through the choroid into deeper layers of the retina. ... systemic side effects. Hence, parameters such as safety and toxicity need to be considered when trying to obtain a therapeutic response in the eye upon oral administration. ... drug. Similarly, mobility of nanoparticles in the vitreous depends on their structure and ...
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: